250915 Initiation of Clinical Research for Innovative New Drugs Based on Herbal Ingredients

Bichedam Co., Ltd. Initiates Phase 1 Clinical Trial of Candidate Drug BCD101 at Chungbuk National University Hospital
Designed for 7 Cohorts with 56 Participants…Evaluating Safety, Tolerability, and Pharmacokinetics

[Korean Medicine News] Bichedam Co., Ltd. (CEO Moon Hobin) held the Site Initiation Visit (SIV) for its herbal ingredient-based ROCK inhibitor, BCD101, at the Clinical Trial Center of Chungbuk National University Hospital on the 5th.

The clinical trial is led by Professor Park Min-gyu of the Department of Clinical Pharmacology at Chungbuk National University Hospital as the principal investigator (PI), and the clinical research organization (CRO) LSK Global PS is conducting the trial.

BCD101 aims to develop treatments for nocturnal leg cramps (NLC) and geriatric hypertension by improving vascular stiffness. In this Phase 1 trial, the drug’s safety, tolerability, and pharmacokinetics (PK) will be assessed in healthy adult volunteers.

During the initiation meeting, Professor Park stated, “This Phase 1 trial is designed for a total of 7 cohorts with 56 participants, and the first patient enrollment and dosing are scheduled for September 23.” He also shared the trial schedule and discussed the research team’s future plans.

A Bichedam representative added, “The start of this Phase 1 trial marks a significant milestone in BCD101’s global new drug development journey. By confirming safety and tolerability, we aim to expand indications and proceed to global clinical trials.”

Source: https://www.akomnews.com/bbs/board.php?bo_table=news&wr_id=64403